REXAHN PHARMACEUTICALS, INC. DEF 14A 6-9-2016

Company

Opus Genetics, Inc.

Filed

April 18, 2016

Period of Report

June 9, 2016

Accession Number

0001140361-16-061408

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →